Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
APGE Stock Forecast 2026-2027
$86.92
Current Price
$6.55B
Market Cap
Buy 15
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to APGE Price Targets
+84.1%
To High Target of $160.00
+38.1%
To Median Target of $120.00
-6.8%
To Low Target of $81.00
APGE Price Momentum
+5.8%
1 Week Change
+2.8%
1 Month Change
+112.1%
1 Year Change
+15.2%
Year-to-Date Change
-8.8%
From 52W High of $95.32
+153.1%
From 52W Low of $34.34
📊 TOP ANALYST CALLS
Did APGE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Apogee Therapeutics is one of their latest high-conviction picks.
Latest APGE Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, APGE has a bullish consensus with a median price target of $120.00 (ranging from $81.00 to $160.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $86.92, the median forecast implies a 38.1% upside. This outlook is supported by 15 Buy, 4 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Danielle Brill at Truist Securities, suggesting a 6.8% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
APGE Analyst Ratings
15
Buy
4
Hold
0
Sell
APGE Price Target Range
Low
$81.00
Average
$120.00
High
$160.00
Current: $86.92
Latest APGE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for APGE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 27, 2026 | Truist Securities | Danielle Brill | Hold | Maintains | $81.00 |
| May 27, 2026 | BTIG | Julian Harrison | Buy | Reiterates | $137.00 |
| May 27, 2026 | Wedbush | David Nierengarten | Outperform | Maintains | $135.00 |
| May 1, 2026 | Rothschild & Co | Buy | Initiates | $N/A | |
| Mar 30, 2026 | Mizuho | Outperform | Maintains | $N/A | |
| Mar 24, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Mar 24, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 24, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Mar 23, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Mar 18, 2026 | Truist Securities | Hold | Initiates | $N/A | |
| Mar 16, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Mar 3, 2026 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Mar 3, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Jan 22, 2026 | RBC Capital | Sector Perform | Downgrade | $N/A | |
| Jan 7, 2026 | Wolfe Research | Peer Perform | Initiates | $N/A | |
| Jan 6, 2026 | BTIG | Buy | Maintains | $N/A | |
| Jan 5, 2026 | BTIG | Buy | Maintains | $N/A | |
| Dec 17, 2025 | Stephens & Co. | Overweight | Initiates | $N/A | |
| Dec 10, 2025 | Deutsche Bank | Buy | Initiates | $N/A | |
| Nov 3, 2025 | Craig-Hallum | Buy | Initiates | $N/A |
Apogee Therapeutics Inc. (APGE) Competitors
The following stocks are similar to Apogee Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
APGE
Apogee Therapeutics
mkt cap
6.19B
Apogee Therapeutics Inc. (APGE) Financial Data
Valuation Metrics
Market Cap
$6.55B
Enterprise Value
$4.85B
P/E Ratio
N/A
PEG Ratio
-16.4x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+16.3%
Current Ratio
32.6x
Debt/Equity
0.6x
ROE
-28.5%
ROA
-19.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Apogee Therapeutics Inc. (APGE) Business Model
About Apogee Therapeutics Inc.
What They Do
Develops biologics for inflammatory and immune diseases.
Business Model
The company operates as a clinical-stage biotechnology firm, focusing on the development of novel antibody therapeutics intended for conditions with significant unmet medical needs. It generates revenue through the advancement of its drug pipeline, which aims to offer improved treatment options that may lead to partnerships, licensing agreements, or eventual market sales once products gain regulatory approval.
Additional Information
Founded in 2022 and headquartered in Waltham, Massachusetts, Apogee Therapeutics is led by a team of experts in clinical, commercial, scientific, and operational fields. The company is committed to transforming care for patients suffering from various immune-mediated diseases, including atopic dermatitis and asthma, by optimizing drug efficacy and reducing treatment frequency.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
261
CEO
Dr. Michael Thomas Henderson M.D.
Country
United States
IPO Year
N/A
Website
www.apogeetherapeutics.comApogee Therapeutics Inc. (APGE) Latest News & Analysis
Latest News
Quick Summary
Apogee Therapeutics (APGE) reported positive results from Part B of its Phase 2 APEX trial for Zumilokibart, targeting atopic dermatitis.
Why It Matters
Positive clinical trial results can boost Apogee Therapeutics' stock price, attract investment, and indicate potential for future revenue growth in the dermatology market.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Apogee Therapeutics reported mixed results for its experimental eczema treatment, leading to a decline in its stock price.
Why It Matters
Mixed results in drug trials can lead to decreased investor confidence, impacting stock performance and future funding prospects for Apogee Therapeutics.
Source: Investors Business Daily
Market Sentiment:
Negative
Quick Summary
Apogee Enterprises (NASDAQ:APOG) has secured up to $1.3 billion in non-dilutive financing from Blackstone Life Sciences, aiding Phase 3 development of its lead candidate, zumilokibart.
Why It Matters
Apogee Enterprises secures $1.3 billion in non-dilutive capital, enhancing financial stability and accelerating drug development, which could lead to significant revenue growth and increased shareholder value.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
Apogee Therapeutics (Nasdaq: APGE) will report 16-week data from the Phase 2 APEX trial of zumilokibart on May 27, 2026, followed by a conference call at 8:00 a.m.
Why It Matters
The upcoming Phase 2 trial data release for Apogee Therapeutics' drug could significantly impact stock valuation and investor sentiment, influencing market positions in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
APEX Part B achieved all primary and secondary endpoints. Mid-dose zumilokibart is set to advance to Phase 3 trials for moderate-to-severe atopic dermatitis in 2H 2026.
Why It Matters
Successful APEX Part B results and planned Phase 3 trials for zumilokibart indicate potential for significant market impact in atopic dermatitis, attracting investor interest in biotech growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A company secured up to $1.3 billion in flexible, non-dilutive capital, comprising up to $800 million in synthetic royalty and $500 million in senior corporate debt.
Why It Matters
The availability of $1.3 billion in flexible capital enhances liquidity and growth potential, reducing dilution risks and providing financial stability, which can positively impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About APGE Stock
What is Apogee Therapeutics Inc.'s (APGE) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Apogee Therapeutics Inc. (APGE) has a median price target of $120.00. The highest price target is $160.00 and the lowest is $81.00.
Is APGE stock a good investment in 2026?
According to current analyst ratings, APGE has 15 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $86.92. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for APGE stock?
Wall Street analysts predict APGE stock could reach $120.00 in the next 12 months. This represents a 38.1% increase from the current price of $86.92. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Apogee Therapeutics Inc.'s business model?
The company operates as a clinical-stage biotechnology firm, focusing on the development of novel antibody therapeutics intended for conditions with significant unmet medical needs. It generates revenue through the advancement of its drug pipeline, which aims to offer improved treatment options that may lead to partnerships, licensing agreements, or eventual market sales once products gain regulatory approval.
What is the highest forecasted price for APGE Apogee Therapeutics Inc.?
The highest price target for APGE is $160.00 from at , which represents a 84.1% increase from the current price of $86.92.
What is the lowest forecasted price for APGE Apogee Therapeutics Inc.?
The lowest price target for APGE is $81.00 from Danielle Brill at Truist Securities, which represents a -6.8% decrease from the current price of $86.92.
What is the overall APGE consensus from analysts for Apogee Therapeutics Inc.?
The overall analyst consensus for APGE is bullish. Out of 4 Wall Street analysts, 15 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $120.00.
How accurate are APGE stock price projections?
Stock price projections, including those for Apogee Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 2:07 AM UTC